AstraZeneca

Nivolumab plus gemcitabine/cisplatin chemotherapy significantly improved response rates, overall survival, and progression-free survival in patients with lymph node–only metastatic urothelial carcinoma, according to a post hoc analysis of the CheckMate 901 trial presented at the 2024 ASCO Annual Meeting.

Brazil hosts over 400 cancer drug clinical trials, leveraging its diverse population and advanced healthcare infrastructure. The country's regulatory framework, led by ANVISA, has improved but still faces delays due to dual approvals. Despite challenges like limited funding and logistical issues, Brazil's commitment to enhancing its clinical trial ecosystem positions it as a key player in global medical research.

TROPION-Lung01 trial results show datopotamab deruxtecan (12.9 months OS) vs. docetaxel (11.8 months OS) in overall population, with nonsquamous histology showing 14.6 months vs. 12.3 months OS. In patients with actionable genomic alterations, datopotamab deruxtecan showed 15.6 months OS compared to 9.8 months with docetaxel. NeoCOAST-2 trial preliminary results indicate 34.1% pCR and 65.9% mPR with datopotamab deruxtecan plus Imfinzi and carboplatin in early-stage NSCLC.

Datopotamab deruxtecan showed a median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in the TROPION-Lung01 Phase III trial. The trial, evaluating AstraZeneca and Daiichi Sankyo's drug versus chemotherapy, met the dual primary endpoint of progression-free survival. Results were presented at the IASLC 2024 World Conference on Lung Cancer.

Johnson & Johnson's Rybrevant and Lazcluze combo showed a 23% OS benefit over AstraZeneca's Tagrisso in advanced non-small cell lung cancer, with 61% survival at three years versus 53%. The combo also reduced CNS disease risk by 18% and received FDA approval for EGFR-mutated NSCLC.

IMFINZI is indicated for various lung cancer treatments, including unresectable Stage III NSCLC, metastatic NSCLC, extensive-stage SCLC, and biliary tract cancer. It also treats unresectable HCC in combination with IMJUDO. TROPION-Lung01 and NeoCOAST-2 are Phase III and II trials evaluating datopotamab deruxtecan and IMFINZI, respectively, in lung cancer. AstraZeneca collaborates with Daiichi Sankyo for ADC development and aims to improve lung cancer outcomes.

Global Monoclonal Antibodies Market to reach USD 804.7 billion by 2033, growing at a CAGR of 12.5% from USD 279.8 billion in 2024. Dominated by North America, human-derived antibodies, and oncology applications, with key players including Roche, Novartis, and Johnson & Johnson.

The global mRNA vaccine market is projected to decline at a CAGR of -4.3% from 2024 to 2034, reaching US$ 9.6 billion by 2034. Factors driving market growth include streamlined approval processes, innovations in logistics, increasing public trust, and ongoing research into long-term efficacy. Key players include Pfizer-BioNTech, Moderna, and Novartis, with North America leading in market share.